Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2021

View Archived Issues

Antidiarrheal drug fights AML

New phase I study evaluates iExosomes in metastatic pancreatic cancer with KrasG12D mutation

Oral islatravir studied in new phase III trials as PrEP for HIV

New CRL4 inhibitors show cytotoxicity tumors with low CUL4 expression

Copper chelator TDMQ-20 reverses impairments in Alzheimer's disease models

Positive phase I data support advancing FOR-6219 to phase II development in endometriosis

Dosing begins in phase I study of DNX-2440 in patients with resectable liver metastasis

Landos reports positive phase I data for NX-13

Bi-functionalized nanoparticles described by Vall d'Hebron Institut de Recerca and collaborators

Eli Lilly presents promising data from SURPASS-2 study of tirzepatide in type 2 diabetes

University of Virginia patents regulatory T cells armed with bispecific antibodies

Yangtze River Pharmaceutical, Shanghai Haiyan Pharmaceutical Technology describe mu-opioid agonists

New JAK-1/TYK2 inhibitors synthesized at the National Institute of Pharmaceutical R&D

Cough triggers and symptoms among patients treated in COUGH-1 and COUGH-2

New NTRK1 inhibitors discovered by Luoxin Pharmaceutical, Shandong Luoxin Pharmacy Group

CYH-33 demonstrates preliminary antitumor activity in PIK3CA-mutant tumors

[68Ga]NOTA-AE-105 PET/MRI useful for prostate cancer evaluation and reduces biopsy needs

Youhe reports partial remission in phase I study of YH-001 with teriprizumab in solid tumors

Apellis ends development of APL-9 for severe COVID-19

FDA approves Actemra for systemic sclerosis-associated interstitial lung disease

NIAID closes ACTIV-3 substudies of BRII-196, BRII-198 and VIR-7831

Novel mutation in the IRF2BPL gene tied to rare neurodevelopmental disorder

Imperial psychedelic microdosing study pushes the envelope on participant blinding

TurnSole initiates phase I/II study of TS-020 in hospitalized COVID-19 patients

NervGen receives FDA feedback on phase I plans with NVG-291

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
SKL-35501 shows broad antitumor activity in solid tumors
BioWorld Science
Neurotensin receptor 1 (NTSR1) is overexpressed in several aggressive solid tumors, including colorectal and pancreatic cancer, making it a promising therapeutic...